Dr Mario Polywka joined the board of Orbit Discovery in September 2019.
Dr Polywka retired from the Management Board of Evotec AG in 2018 where he served as member of the Management Board and Chief Operating Officer since 28 November 2007. In 1991, he was a founding chemist of Oxford Asymmetry International plc (OAI), became Director of Chemistry in 1993 and a Board Director in 1996. In 1999, Dr Polywka was appointed Chief Operating Officer and in 2001 Chief Executive Officer of OAI. Following the merger of EVOTEC BioSystems AG with OAI in 2000 he was Chief Operating Officer until 2002. Between 2002 and 2004, Dr Polywka ran a number of spin-out companies from Oxford and Southampton Universities.
Dr Polywka received his Bachelor’s degree from Hertford College, Oxford University and his Doctorate from the University of Oxford in mechanistic organometallic chemistry with Professor Steve Davies and continued at Oxford with post-doctoral studies on the biosynthesis of Penicillin with Professor Sir Jack Baldwin. He held a number of college teaching posts at Oxford University between 1988 and 1994. Dr Polywka is a Fellow of the Royal Society of Chemistry and has a number of publications and patents mainly in the field of asymmetric synthesis.
In May 2017, Dr Mario Polywka became a member of the Board of Directors of Forge Therapeutics, Inc. and in September 2017, Dr Mario Polywka also joined the Board of Directors of Exscientia Ltd.